Non-Invasive Prenatal Testing (NIPT) is an advanced screening test at around 10 weeks of pregnancy that isolates and analyses small fragments of placental DNA found in a pregnant mother’s blood. The placenta is a vital organ which connects a developing baby to its mother. This DNA is not found within the cells in mum’s blood, but is floating freely in her bloodstream. It is called cell-free DNA and 99% of the time is exactly the same as the baby’s genetic makeup.
Carefully isolating this DNA from the mother’s blood means it can be checked for certain chromosome abnormalities, as early as 10 weeks of pregnancy. Because it only requires a blood sample from the mother, NIPT does not pose a risk to the pregnancy, making it a safe and highly informative test for expectant parents who want to know more about their baby’s DNA. The importance of this test result mean it should not be regarded as “just another” blood test. It is an emotional journey for expectant parents which can have enormous implications on the outcome of the pregnancy. Therefore, choosing the correct test & provider is a lot more important than just finding the cheapest and quickest.
One of the major benefits of NIPT is its high screening accuracy when compared to more traditional first-trimester tests. NIPT can screen for the most common chromosome abnormalities, including Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). Other NIPT options also look at the baby’s sex chromosomes, for conditions such as Turner syndrome (monosomy X), Klinefelter syndrome (XXY), and other variations involving the X and Y chromosomes. Some NIPT tests additionally offer screening for selected microdeletions. These are genetic disorders caused by the loss of a tiny piece of a chromosome containing multiple genes.
While the technology behind NIPT is sophisticated, the expertise of the laboratory performing the test is just as important. Choosing a provider with a dedicated NIPT team and many years of experience can significantly impact the quality and reliability of results. Experienced laboratories have robust quality systems, refined analysis processes, and a deep understanding of the complexities of cell-free DNA testing, all of which contribute to greater confidence in the result.
The implications of an NIPT result, whether it indicates a low chance or a high chance of a chromosome problem, can be emotionally challenging for parents. A suitably qualified laboratory should do more than provide a report; it should provide clear explanations and access to knowledgeable professionals who can discuss the result and its meaning. It is important to understand that NIPT is a screening test not a diagnostic test, and experienced teams can guide families on appropriate follow-up options, such as diagnostic testing or specialist referral, when required.
When selecting an NIPT provider, the decision should not be based solely on cost or speed of results. Accuracy, quality assurance, and access to expert support are far more important. Having confidence in the result and the opportunity to discuss it with a dedicated NIPT team can reduce anxiety and help expectant parents make informed decisions.
Ultimately, NIPT empowers parents with early, reliable information. Choosing an experienced laboratory ensures that this information is delivered with accuracy, care, and the support every family deserves.
The Forensic Genomics Innovation Hub is proud to be introducing their new NIPT test very soon. It will be available either directly through us or our partner scanning clinics. If you want to learn more about our new highly sensitive and accurate NIPT test, please contact us at lab@fgih.co.uk for more information.
Suffering from psychological stress could further increase cancer risk if you already have a genetic predisposition to the disease, according to new research. The stress hormone cortisol increases the risk of breast and prostate cancer in people with BRCA mutations.
The Forensic Genomics Innovation Hub proudly attended the recent BSACI Annual Conference as leading provider of molecular allergology testing services to Healthcare specialists. Read more about the event.
Have you been prescribed Tamoxifen? Did you know that genetic testing can identify how your body processes the medication. Are you getting the full benefit from the Tamoxifen or is your DNA leaving you at a higher risk of your cancer recurring?
NICE approves Itulazax®, the first daily tablet for birch pollen allergy. This tablet could help 27,000 people in England achieve long-term symptom relief. Are you eligible?